Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.
Yuta AdachiNaohiro YanagimuraChiaki SuzukiSakiko OotaniAzusa TanimotoAkihiro NishiyamaKaname YamashitaKoushiro OhtsuboShinji TakeuchiSeiji YanoPublished in: BMC cancer (2020)
The reduction of the doses of dabrafenib and trametinib was effective in the treatment of BRAF V600E-mutant NSCLC, and also prevented the incidence of rhabdomyolysis.